Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

15,340 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Considerations on the use of urine markers in the management of patients with low-/intermediate-risk non-muscle invasive bladder cancer.
Schmitz-Dräger BJ, Todenhöfer T, van Rhijn B, Pesch B, Hudson MA, Chandra A, Ingersoll MA, Kassouf W, Palou J, Taylor J, Vlahou A, Behrens T, Critelli R, Grossman HB, Sanchez-Carbayo M, Kamat A. Schmitz-Dräger BJ, et al. Among authors: taylor j. Urol Oncol. 2014 Oct;32(7):1061-8. doi: 10.1016/j.urolonc.2013.10.010. Epub 2014 Jan 9. Urol Oncol. 2014. PMID: 24411790 Review.
Considerations on the use of urine markers in the management of patients with high-grade non-muscle-invasive bladder cancer.
Kamat AM, Vlahou A, Taylor JA, Hudson ML, Pesch B, Ingersoll MA, Todenhöfer T, van Rhijn B, Kassouf W, Barton Grossman H, Behrens T, Chandra A, Goebell PJ, Palou J, Sanchez-Carbayo M, Schmitz-Dräger BJ. Kamat AM, et al. Among authors: taylor ja. Urol Oncol. 2014 Oct;32(7):1069-77. doi: 10.1016/j.urolonc.2014.06.017. Epub 2014 Oct 11. Urol Oncol. 2014. PMID: 25306288 Review.
Innovation in Bladder Cancer Immunotherapy.
Grossman HB, Lamm DL, Kamat AM, Keefe S, Taylor JA 3rd, Ingersoll MA. Grossman HB, et al. J Immunother. 2016 Oct;39(8):291-7. doi: 10.1097/CJI.0000000000000130. J Immunother. 2016. PMID: 27428265 Review.
Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma.
Kamat AM, Bellmunt J, Galsky MD, Konety BR, Lamm DL, Langham D, Lee CT, Milowsky MI, O'Donnell MA, O'Donnell PH, Petrylak DP, Sharma P, Skinner EC, Sonpavde G, Taylor JA 3rd, Abraham P, Rosenberg JE. Kamat AM, et al. Among authors: taylor ja 3rd. J Immunother Cancer. 2017 Aug 15;5(1):68. doi: 10.1186/s40425-017-0271-0. J Immunother Cancer. 2017. PMID: 28807024 Free PMC article.
Erratum to: Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma.
Kamat AM, Bellmunt J, Galsky MD, Konety BR, Lamm DL, Langham D, Lee CT, Milowsky MI, O'Donnell MA, O'Donnell PH, Petrylak DP, Sharma P, Skinner EC, Sonpavde G, Taylor JA 3rd, Abraham P, Rosenberg JE. Kamat AM, et al. Among authors: taylor ja 3rd. J Immunother Cancer. 2017 Sep 28;5(1):80. doi: 10.1186/s40425-017-0280-z. J Immunother Cancer. 2017. PMID: 28962591 Free PMC article. No abstract available.
What Is the Significance of Variant Histology in Urothelial Carcinoma?
Lobo N, Shariat SF, Guo CC, Fernandez MI, Kassouf W, Choudhury A, Gao J, Williams SB, Galsky MD, Taylor JA 3rd, Roupret M, Kamat AM. Lobo N, et al. Among authors: taylor ja 3rd. Eur Urol Focus. 2020 Jul 15;6(4):653-663. doi: 10.1016/j.euf.2019.09.003. Epub 2019 Sep 15. Eur Urol Focus. 2020. PMID: 31530497 Review.
15,340 results
You have reached the last available page of results. Please see the User Guide for more information.